Precision Cardiovascular Medicine Emerges as New Paradigm to Address Disease Heterogeneity and Drug Development Challenges
核心洞察
Cardiovascular diseases (搜索) remain the leading cause of death globally with 19 million deaths in 2020, despite advances in drug development, highlighting the need for precision medicine approaches that address disease heterogeneity at molecular, cellular, and patient levels.
Systems biology approaches integrating multiomics data, network medicine, and artificial intelligence are enabling identification of novel biomarkers and drug targets while improving patient stratification and therapeutic development timelines.
New therapeutic platforms including RNA-targeted interventions, computational drug discovery, and cell-type-specific delivery methods offer promise for overcoming traditional druggability barriers and reducing development costs from current 9.1-year averages.
Cardiovascular diseases (搜索) collectively remain the leading cause of death globally, resulting in 19 million deaths worldwide in 2020 despite significant advances in drug development and risk factor management. This persistent burden has prompted researchers to advocate for a fundamental shift toward precision cardiovascular medicine to address the complex heterogeneity that characterizes these conditions.
The challenge stems from multilevel heterogeneity in cardiovascular diseases (搜索), ranging from complex pathobiological mechanisms at molecular and cellular levels to diverse clinical presentations and therapeutic responses at individual and population levels. This variability arises from individuals' unique genomic characteristics, such as single-nucleotide polymorphisms, and exposomic factors including environmental exposures like air pollution or pesticides.
Systems Biology Transforms Disease Understanding
A comprehensive systems approach involving unbiased omics analyses, bioinformatics, and network science is emerging as a solution to traditional reductionist methods. This integrated framework enables simultaneous analysis of entities from different omics layers, including genes, proteins, and metabolites, to construct comprehensive disease models.
Network medicine approaches have proven particularly valuable for analyzing rich omics data generated in recent decades. These methods help identify key molecules, subnetworks, and pathways related to cardiovascular disease, providing crucial information for novel drug target identification. Recent applications include studying genetic risk loci from genome-wide association studies for features such as atrial fibrillation (搜索) and analyzing proteomic data to reveal global impacts of macrophage activation in vascular disease.
The systems approach enables discovery of both diagnostic and prognostic biomarkers while facilitating identification of promising targets with improved accuracy in predicting drug efficacy in patients. By analyzing connections between drug target genes and potentially beneficial clinical outcomes, researchers can better predict which proteins are likely to succeed in clinical development.
Proteomics Headlines Multiomics Revolution
Mass spectrometry-enabled protein research has emerged as a particularly promising avenue for identifying novel biomarkers and therapeutic targets. Proteins serve as major determinants of cellular phenotype, with unbiased proteomic approaches consistently used to identify molecular drivers of conditions including coronary heart disease (搜索), abdominal aortic aneurysms, and calcific aortic valve disease.
Targeted proteomics has already demonstrated clinical value, particularly in monitoring steady-state kinetics of candidate LDL-cholesterol lowering targets such as apolipoprotein B (搜索), cholesteryl-ester transfer protein (搜索), and PCSK9 in cardiovascular outcome trials. The field is advancing toward analyzing specific protein isoforms, known as proteoforms, which may result from genetic variants, messenger RNA splice variants, and post-translational modifications.
Single-Cell Technologies Address Cellular Heterogeneity
The development of single-cell analysis platforms represents a major breakthrough in understanding disease heterogeneity. Traditional assays examining average levels of gene or protein expression in entire cell populations cannot assess how individual cells behave, limiting understanding of complex disease mechanisms.
Recent evidence suggests that macrophage heterogeneity extends beyond the traditional pro-inflammatory M1 and anti-inflammatory M2 dichotomy, involving more complex subpopulations. The balance between these subsets in local microenvironments, such as atherosclerotic plaques, may determine disease progression risk or onset of clinical complications like myocardial infarction (搜索).
Single-cell technologies now enable deeper sequencing in more cells, platforms for simultaneous surveying of various omics layers, and computational infrastructure for innovative data analyses. These advances include droplet-based and well-based platforms, surface receptor profiling, chromatin accessibility mapping, and emerging single-cell proteomics and metabolomics capabilities.
Artificial Intelligence Accelerates Discovery
The application of artificial intelligence in cardiovascular sciences focuses primarily on prediction and clustering tasks. Prediction tools estimate future prognosis and survivability of conditions including heart failure (搜索) and cardiomyopathies (搜索), while also assisting diagnosis through medical imaging data analysis using echocardiograms, computed tomography, or magnetic resonance imaging.
AI-powered approaches utilize clinical data sources including electronic health records to address disease heterogeneity at the population level. The 21st Century Cures Act, initiated in 2016, promoted the use of such "real-world data" in drug development and regulatory decision-making. Generative AI programs can autonomously create new content by learning patterns from existing data, potentially revolutionizing drug discovery processes.
Computational Drug Discovery Overcomes Traditional Barriers
The pharmaceutical industry faces major challenges with drug discovery costs and timelines averaging 9.1 years for innovative medicines, coupled with approximately 90% failure rates between phase I trials and regulatory approval. Computational approaches are increasingly contributing to various aspects of drug discovery to address these challenges.
Quantitative structure-property relationship and quantitative structure-activity relationship methods correlate molecular structure with properties or biological activity using quantifiable descriptors. The Connectivity Map database includes changes in gene expression profiles when various compounds are exposed to different cell types, enabling rapid drug repurposing through phenotypic screening approaches.
Drug-target interaction prediction utilizes ligand-based, docking-based, and chemogenomic approaches. Chemogenomic methods, which use compound physicochemical features and protein genomic features, have attracted particular attention for overcoming limitations of other approaches. Various machine learning frameworks, including deep learning techniques, have significantly improved prediction accuracy.
RNA Therapeutics Expand Treatment Options
RNA-targeted interventions represent a new class of innovative therapeutics that may overcome traditional drug development limitations. Advantages include the potential to target any gene of interest, lower manufacturing costs compared to protein-targeted therapeutics, and substantially shorter development times than conventional medicines.
The first antisense oligonucleotide drug, fomivirsen, was approved in the late 1990s for cytomegalovirus retinitis treatment. Mipomersen, targeting apolipoprotein-B-100 mRNA, became the first RNA-targeted therapy approved for a cardiovascular disease - familial hypercholesterolemia (搜索). Inclisiran, a small interfering RNA targeting PCSK9, has proven safe and effective for lowering LDL cholesterol by approximately 50%.
Pelacarsen, a developmental antisense oligonucleotide directed against lipoprotein(a), targets production of apolipoprotein(a) (搜索), a key component linked clinically with cardiovascular disease including aortic stenosis (搜索). Phase 2 trials demonstrated safety and up to 80% reduction in lipoprotein(a) levels.
Implementation Requires Global Collaboration
Transforming to a precision-based research and innovation paradigm requires greater interdisciplinary collaboration, data science implementation at every stage, and new partnerships between academia and industry. The major gap between target discovery research in academia and drug development in industry represents a significant obstacle, with many academic discoveries failing to bridge this divide due to lack of expertise, funding limitations, and industry risk aversion.
Several models of academia-industry collaboration have emerged to merge sector strengths, with studies indicating higher clinical development success rates compared to either sector working independently. Global policy leadership is essential to implement suitable models of research funding and organization, data infrastructures and policies, medicines regulations, and patient access policies promoting equity.
The COVID-19 pandemic demonstrated the potential for accelerated development when resources are mobilized effectively. Open science approaches that enabled data and idea sharing between academic institutions, pharmaceutical industry, and governmental institutions helped accelerate RNA therapeutic development and implementation, providing a model for future collaborative efforts in cardiovascular medicine.